-
Outrage in Italy after Trump says Meloni 'begged' for photo op
-
Turkey bars public World Cup screening over university entrance exam
-
From birds to fish, how extreme heat causes wildlife to suffer
-
Ebola spreading 'fast' in DR Congo, warns WHO
-
Trapped on Everest for days, Nepali survivor recounts escape
-
The Sun may not engulf Earth after all, scientists say
-
Clark leads by three as US Open second round begins
-
Russia signals slower rate cuts amid high Ukraine war spending
-
Fritz gets revenge on Shelton to reach Halle semis
-
Henry strikes as New Zealand lead England by 100 runs in 2nd Test
-
Heatwave hits more than half of France's population
-
Online threats, insults fuel S.Africa's anti-foreigner hate
-
Former England keeper Earps agrees to join London City Lionesses
-
Clark completes first round with two-stroke US Open lead
-
Olympic hurdles medallist Bascou suspended for doping
-
Italian FM cancels US visit over reported Trump comments
-
Pegula sinks Keys to reach Berlin Open semis
-
Oil prices, shares steady after US-Iran talks postponed
-
Gaza ceasefire a 'deadly illusion': UNICEF
-
What did we learn from the hantavirus cruise ship scare?
-
S.Africa anti-migrant hate loses team African support at World Cup
-
Arsenal will start Premier League title defence against Coventry
-
European robotics start-ups go up against Chinese heavyweights
-
'Alter-Ego': An Italian hospital's little robot carer
-
Japan's men told to clean at home, not just the World Cup
-
French court confirms Moroccan football star Hakimi will stand trial for rape
-
South Korean leader says told Trump sanctions on North are 'ineffective'
-
Deadly Philippines quake turns seabed into shore
-
Stocks rally falters, oil rises as US-Iran talks postponed
-
S. Korean leader says he told Trump sanctions on North are 'ineffective'
-
Indonesia to capture last-known wild Bornean rhino for IVF
-
No vaccine, conflict, mistrust: Ebola's return to DR Congo
-
USA, Australia eye World Cup knockout rounds, Brazil in action
-
AI museum brings sights, sounds and smells of the rainforest
-
Iran to lodge complaint with FIFA over World Cup restrictions
-
'Old dog' Slipper out of retirement for Wallabies' Nations Championship campaign
-
New Zealand minister defends fishers after two orcas killed in net
-
Mexico into World Cup last 32, Canada celebrate historic win
-
Seoul record leads most Asian markets higher, crude extends losses
-
Co-hosts Mexico first team into World Cup knockout rounds
-
Burnham wins key UK poll, paving way for bid to challenge PM Starmer
-
Erasmus under 'no illusions' as tough Springboks season kicks off
-
'Pico' Lopes -- Cape Verde defender's journey from Ireland to World Cup
-
100 Colombian guerrillas disarm in deal with leftist government
-
'Pretty special': captains eye Super Rugby glory in clash of top seeds
-
Football 'ambassador' and fan favorite: a duck becomes a star in Mexico
-
Ivory Coast's Diomande living World Cup dream, dealing with tragedy
-
Slipper out of retirement for Wallabies' Nations Championship campaign
-
Australia seek 'respect' from US amid World Cup 'layup' row
-
New Zealand's Payne joins Paraguayan powerhouse after Instagram fame
US authorizes first condom for use in anal sex
The US Food and Drug Administration (FDA) on Wednesday authorized the first condom for use during anal intercourse, in what was hailed as a victory for sexual health by experts.
Although people already use condoms for anal sex -- as is recommended by health agencies including the Centers for Disease Control and Prevention (CDC) -- regulators across the world had only previously allowed companies to officially market their products as "safe and effective" for vaginal use.
Sexual health advocates considered this an unmet public health need since unprotected anal intercourse carries the greatest risk of HIV transmission via sexual exposure, with one study finding that 69 percent of men who have sex with men would use condoms more frequently if they were FDA-indicated.
Wednesday's authorization of Global Protection Corp's One Male Condom follows a clinical trial involving more than 500 people, carried out by Emory University.
"The FDA's authorization of a condom that is specifically indicated, evaluated and labeled for anal intercourse may improve the likelihood of condom use during anal intercourse," said agency scientist Courtney Lias in a statement.
The condom is also indicated to prevent sexually transmitted infections -- and as a contraceptive -- during vaginal sex.
"We want people to have lots of sex -- but we also want them to be empowered and informed," said Davin Wedel, president of Global Protection Corp, which makes the condom brand that is available in 54 sizes, and incorporates a paper template to help each user find the right size.
The clinical trial involved 252 men who have sex with men and 252 men who have sex with women, aged between 18 and 54.
The FDA had said it would accept a five percent failure rate, which previous trials had failed to accomplish. The limit was easily surpassed in the new study, with the failure rate 0.68 percent for anal and 1.89 percent for vaginal intercourse.
The researchers behind the study, which was published in The Lancet's eClinicalMedicine, said one of the reasons the trial succeeded where others failed in the past was likely due to the provision of lubricant and inclusion of instructions on how to use the product.
Lubricant reduces friction, which in turn causes condom failure from slippage and breakage.
Another reason could be that participants were asked to keep mobile phone-based daily diaries, whereas past trials had asked volunteers to recall failure events up to several months later.
Monica Gandhi, an infectious disease doctor and medical director of an HIV clinic in San Francisco, welcomed the finding.
"The important thing about condoms is they don't just prevent HIV, but they prevent gonorrhea, chlamydia and syphilis," she told AFP, adding it was surprising that such an authorization had taken so long to achieve.
In its statement, the FDA said the green light could pave the way for more makers to apply for similar authorization if they show equivalent results.
K.Thomson--BTB